Coltac Therapeutics is a startup based in Israel.
Coltac Therapeutics is a company headquartered in Israel.
Coltac Therapeutics develops molecular-glue therapeutics by using a proprietary high-throughput E. coli-based positive-selection screening system. The company combines structural biology and computational approaches to select E3 ligase libraries and identify compounds that enhance E3–target binding for targeted protein degradation in cancer.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.